{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:15:47Z","timestamp":1791821747776,"version":"4.3.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012964","name":"Minist\u00e8re de l\u2019Enseignement Sup\u00e9rieur et de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012964","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.05.092","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T18:42:39Z","timestamp":1560278559000},"page":"6987-6995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media"],"prefix":"10.1016","volume":"37","author":[{"given":"Samia","family":"Rourou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Ben Zakkour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9la","family":"Kallel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2019.05.092_b0005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/rmb2.12024","article-title":"Animal-cell culture media: history, characteristics, and current issues","volume":"16","author":"Yao","year":"2017","journal-title":"Reprod Med Biol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0010","series-title":"Cell Culture technology, learning materials in biosciences","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-74854-2_1","article-title":"Cell Culture bioprocess technology: biologics and beyond","author":"O\u2019Brien","year":"2018"},{"key":"10.1016\/j.vaccine.2019.05.092_b0015","series-title":"Industrial scale suspension culture of living cells","first-page":"503","article-title":"Virus production under suspension conditions","author":"Merten","year":"2014"},{"key":"10.1016\/j.vaccine.2019.05.092_b0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.109.2822.85","article-title":"Cultivation of Lansing strain of poliomyelitis virus in culture of various human embryonic tissues","volume":"109","author":"Enders","year":"1949","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.05.092_b0025","series-title":"Basic and applied aspects of biotechnology","first-page":"59","article-title":"Animal cell culture and cryopreservation","author":"Gupta","year":"2017"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.092_b0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12934-016-0437-3","article-title":"Recombinant pharmaceuticals from microbial cells: a 2015 update","volume":"15","author":"Sanchez-Garcia","year":"2016","journal-title":"Microb Cell Fact"},{"key":"10.1016\/j.vaccine.2019.05.092_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00314","article-title":"The market of biopharmaceutical medicines: a snapshot of diverse industrial landscape","volume":"8","author":"Moorkens","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.05.092_b0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/erv.09.19","article-title":"Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines","volume":"8","author":"Barrett","year":"2009","journal-title":"Exp Rev Vacc"},{"issue":"9","key":"10.1016\/j.vaccine.2019.05.092_b0045","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Exp Rev Vacc"},{"issue":"44","key":"10.1016\/j.vaccine.2019.05.092_b0050","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2015.06.110","article-title":"Cell substrates for the production of viral vaccines","volume":"33","author":"Aubrit","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.05.092_b0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2217\/fvl-2016-0006","article-title":"Cell culture-based viral vaccines: current status and future prospects","volume":"11","author":"Zahoor","year":"2016","journal-title":"Fut Virol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0060","first-page":"1201","article-title":"Study of SV40 in tissue culture","volume":"21","author":"Yasumura","year":"1963","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.vaccine.2019.05.092_b0065","unstructured":"World Health Organization. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. WHO Technical Report Series, No. 978. Geneva: WHO; 2013 [Annex 3]."},{"key":"10.1016\/j.vaccine.2019.05.092_b0070","first-page":"99","article-title":"Requirements for continuous cell lines used for biological substances","volume":"745","author":"World Health Organization","year":"1987","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.vaccine.2019.05.092_b0075","first-page":"167","article-title":"Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines","volume":"760","author":"World Health Organization","year":"1987","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.vaccine.2019.05.092_b0080","series-title":"Recombinant glycoprotein production: methods and protocols, methods in molecular biology","first-page":"75","article-title":"Strategies to suspension serum-free adaptation of mammalian cell lines for recombinant glycoprotein production","author":"Caron","year":"2018"},{"issue":"8","key":"10.1016\/j.vaccine.2019.05.092_b0085","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00449-015-1392-9","article-title":"Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation","volume":"38","author":"Biaggio","year":"2015","journal-title":"Bioprocess Biosyst Eng"},{"key":"10.1016\/j.vaccine.2019.05.092_b0090","first-page":"41","article-title":"A new method for the cultivation of mammalian cells suspended in agitated fluid medium","volume":"1","author":"Owens","year":"1953","journal-title":"Proc Am Assn Cancer Res"},{"key":"10.1016\/j.vaccine.2019.05.092_b0095","first-page":"1159","article-title":"The growth of pure strain L cells in fluid suspension cultures","volume":"14","author":"Earle","year":"1954","journal-title":"J Nat Cancer Inst"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.092_b0100","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0022-4804(65)80017-8","article-title":"Suspension cultures of mammalian cells","volume":"5","author":"Moore","year":"1965","journal-title":"J Surg Res"},{"key":"10.1016\/j.vaccine.2019.05.092_b0105","first-page":"163","article-title":"The use of BHK suspension cells for the commercial production of foot and mouth disease vaccines over a twenty year period","volume":"60","author":"Radlett","year":"1985","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2019.05.092_b0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00570893","article-title":"The growth of Vero cells in suspension as cell-aggregates in serum-free media","volume":"10","author":"Litwin","year":"1992","journal-title":"Cytotechnology"},{"issue":"46","key":"10.1016\/j.vaccine.2019.05.092_b0115","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1016\/j.vaccine.2009.06.020","article-title":"Suspension-Vero cell cultures as a platform for viral vaccine production","volume":"27","author":"Paillet","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.092_b0120","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1016\/j.vaccine.2011.07.016","article-title":"Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero)","volume":"29","author":"Paillet","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.092_b0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2010.09.029","article-title":"Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK-21 cell lines","volume":"171","author":"Van Wielink","year":"2011","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.092_b0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pep.2013.09.001","article-title":"Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells","volume":"92","author":"Hacker","year":"2013","journal-title":"Protein Expr Purif"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.092_b0135","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/v6041672","article-title":"Matrix and backstage: cellular substrates for viral vaccines","volume":"6","author":"Jordan","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.05.092_b0140","unstructured":"WHO Expert Consultation on Rabies: third report. Geneva: World Health Organization; Technical report series N 1012; 2018."},{"issue":"12","key":"10.1016\/j.vaccine.2019.05.092_b0145","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.20546\/ijcmas.2017.612.237","article-title":"Review on rabies and vaccines","volume":"6","author":"Abraham","year":"2017","journal-title":"Int J Curr Microbiol App Sci"},{"issue":"S1","key":"10.1016\/j.vaccine.2019.05.092_b0150","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1016\/j.vaccine.2018.08.039","article-title":"New human rabies vaccines in the pipeline","volume":"37","author":"Fooks","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.092_b0155","unstructured":"WHO Weekly epidemiological record. No 16, 93; 2018. p. 201\u201320."},{"key":"10.1016\/j.vaccine.2019.05.092_b0160","unstructured":"WHO. Human rabies: 2016 updates and call for data. Weekly epidemiological record. No 7, 92; 2017. p. 77\u201388."},{"key":"10.1016\/j.vaccine.2019.05.092_b0165","series-title":"Laboratory techniques in rabies","author":"Rupprecht","year":"2018"},{"issue":"4","key":"10.1016\/j.vaccine.2019.05.092_b0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1134\/S0026893315040172","article-title":"Rabies vaccines: current status and prospects for development","volume":"49","author":"Starodubova","year":"2015","journal-title":"Mol Biol"},{"issue":"S1","key":"10.1016\/j.vaccine.2019.05.092_b0175","doi-asserted-by":"crossref","first-page":"A85","DOI":"10.1016\/j.vaccine.2018.10.014","article-title":"The WHO position on rabies immunization \u2013 2018 updates","volume":"37","author":"O'Brien","year":"2019","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.092_b0180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1586\/14760584.2016.1140040","article-title":"Current status and development of vaccines and other biologics for human rabies prevention","volume":"15","author":"Rupprecht","year":"2016","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.05.092_b0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0168-1656(02)00009-3","article-title":"Evaluation of various serum and animal protein free media for the production of a veterinary rabies vaccine in BHK-21 cells","volume":"95","author":"Kallel","year":"2002","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0190","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00253-003-1245-3","article-title":"A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor","volume":"61","author":"Kallel","year":"2003","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0195","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.enzmictec.2004.11.008","article-title":"Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor","volume":"36","author":"Trabelsi","year":"2005","journal-title":"Enzyme Microb Technol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jbiotec.2005.07.018","article-title":"Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor","volume":"121","author":"Trabelsi","year":"2006","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0205","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1016\/j.vaccine.2007.01.086","article-title":"A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions","volume":"25","author":"Rourou","year":"2007","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.092_b0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00253-009-2064-y","article-title":"A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor","volume":"85","author":"Rourou","year":"2009","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0215","series-title":"Laboratory techniques in rabies","first-page":"354","article-title":"A rapid tissue culture test for determining rabies neutralizing antibody","author":"Smith","year":"1973"},{"issue":"6","key":"10.1016\/j.vaccine.2019.05.092_b0220","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/btpr.279","article-title":"Development of an animal-component free medium for Vero cells culture","volume":"25","author":"Rourou","year":"2009","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2019.05.092_b0225","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1872-2075(06)60007-1","article-title":"Effects of hydrodynamics on aggregates formation, growth and metabolism of HEK 293 cells in suspension culture","volume":"22","author":"Liu","year":"2006","journal-title":"Chin J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.05.092_b0230","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/14760584.2015.1067144","article-title":"Bioreactor concepts for cell culture-based viral vaccine production","volume":"14","author":"Gallo-Ramirez","year":"2015","journal-title":"Exp Rev Vacc"},{"issue":"38","key":"10.1016\/j.vaccine.2019.05.092_b0235","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","article-title":"A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor","volume":"28","author":"Lohr","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.092_b0240","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/bit.1179","article-title":"Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells","volume":"75","author":"Meissner","year":"2001","journal-title":"Biotechnol Bioeng"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2019.05.092_b0245","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00762389","article-title":"Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells","volume":"15","author":"Garnier","year":"1994","journal-title":"Cytotechnology"},{"issue":"13","key":"10.1016\/j.vaccine.2019.05.092_b0250","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0264-410X(94)00022-F","article-title":"An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system","volume":"13","author":"Perrin","year":"1995","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2019.05.092_b0255","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.vaccine.2017.03.018","article-title":"Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells","volume":"36","author":"Nikolay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.092_b0260","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/j.vaccine.2014.02.040","article-title":"An animal component free medium that promotes the growth of various animal cell lines for the production of viral vaccines","volume":"32","author":"Rourou","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.05.092_b0265","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/bp9900460","article-title":"Production of a human growth hormone antagonist from CHO cells adapted to serum-free suspension culture","volume":"15","author":"HaldankarR","year":"1999","journal-title":"Biotechnol Prog"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.092_b0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1472-6750-12-79","article-title":"Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells","volume":"12","author":"Lohr","year":"2012","journal-title":"BMC Biotechnol"},{"issue":"46","key":"10.1016\/j.vaccine.2019.05.092_b0275","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1016\/j.vaccine.2009.06.023","article-title":"Production of yellow fever virus in microcarrier-based Vero cell cultures","volume":"27","author":"Souza","year":"2009","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2019.05.092_b0280","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1016\/j.vaccine.2017.02.042","article-title":"Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture","volume":"36","author":"Liu","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.092_b0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00772195","article-title":"Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines","volume":"14","author":"Merten","year":"1994","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2019.05.092_b0290","doi-asserted-by":"crossref","unstructured":"WHO. Rabies vaccines: WHO position paper, April 2018 \u2013 recommendations. Vaccine 2018; 36(37):5500-5503. doi:10.1016\/j.vaccine.2018.06.061. Epub 2018 Aug 11.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"issue":"5","key":"10.1016\/j.vaccine.2019.05.092_b0295","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.vaccine.2009.11.023","article-title":"Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production","volume":"28","author":"Liu","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:06Z","timestamp":1759401426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":59,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19307492"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.092","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}